stockrow
Friday 6 November 2026
Export LKFT’s income statement to Excel — free account
Lakefront Biotherapeutics - Sponsored ADR
LKFT Healthcare Biotechnology
Lakefront Biotherapeutics - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.3 billion, up 321.9% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- +198.9%
- Free cash flow
- +18.2%
Quarter to June 2026, against a year earlier
33.36
0.20
−0.60%
Follow LKFT
Alert me
| Older periods | Jun '25 | Sep '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | — |
P/S ratio |
— | — | 7.01 | — | |
P/FCF ratio |
— | — | 0.00 | — | |
P/Operating CF |
— | — | (20.40) | — | |
P/B ratio |
— | — | 0.52 | — | |
Price to Tangible BV |
— | — | 0.52 | — | |
EV/Sales |
— | — | (5.35) | — | |
EV/EBITDA |
— | — | 3.62 | — | |
EV/Operating CF |
— | — | 2.96 | — | |
EV/FCF |
— | — | 2.49 | — | |
Quick Ratio |
7.94 | 8.53 | 30.23 | 32.65 | |
Current Ratio |
8.08 | 8.63 | 30.48 | 32.84 | |
Net Debt/EBITDA |
0.00 | 0.00 | 46.74 | 0.00 | |
Debt/Assets |
0.16% | 0.00% | 0.14% | 0.14% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.07 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | (5.71) | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
— | — | (465.12) | — | |
Research and Development Expense of Revenue |
— | — | 477.73% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 547.83% | — | |
Intangible Assets out of Total Assets |
0.06 | 0.00 | 0.00 | 0.22 | |
Share Based Compensation of Revenue |
— | — | 0.00% | — | |
Graham Net Nets |
— | — | 1.74 | — | |
Graham Number |
— | — | 0.00 | — | |
Earnings Yield |
— | — | (0.95%) | — | |
Free Cash Flow Yield |
— | — | (30.60%) | — | |
Revenue per Share |
— | — | 0.12 | — | |
Operating CF per Share |
0.00 | 0.00 | (1.47) | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.02 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (1.45) | 0.00 | |
Cash per Share |
0.00 | 0.00 | 52.99 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 57.81 | 0.00 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 57.81 | 0.00 | |
Free Cash Flow |
(131.79) | (259.70) | (95.45) | (37.79) | |
Working Capital |
3,238.00 | 3,267.61 | 3,464.75 | 2,603.33 | |
Capital Expenditures |
(5.15) | (14.24) | 1.40 | 1.22 | |
Net Current Asset Value |
2,362.25 | 2,451.27 | 3,442.94 | 2,583.29 | |
EV/EBIT |
— | — | 5.94 | — | |
Capex to Sales |
0.00 | 0.00 | (0.18) | 0.00 | |
Price to Operating Income |
— | — | 0.00 | — | |
| Other line items | |||||
Average Receivables |
99.83 | 100.07 | 79.58 | 76.71 | |
Average Payables |
154.60 | 127.90 | 119.74 | 127.56 | |
Average Inventory |
62.91 | 47.53 | 46.40 | 25.26 | |
Average Assets |
4,534.80 | 4,362.69 | 4,267.42 | 4,066.77 | |
Average Common Equity |
3,072.19 | 2,997.18 | 3,477.71 | 3,344.76 |
Columns are period end dates · fundamentals updated 26 Oct 2026